By Chris Wack

 

Prothena Corporation Plc said Bristol Myers Squibb Co. exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005.

Bristol Myers will pay Prothena $80 million for PRX005, designed to be an anti-tau antibody by specifically targeting an area within the microtubule binding region for the potential treatment of Alzheimer's disease.

Prothena said phase 1 study with PRX005 has begun.

The company said PRX005 has demonstrated superior ability to bind, intercept and block cellular internalization of pathogenic tau, and mitigate downstream neurotoxicity compared to other anti-tau antibodies in multiple preclinical studies.

Prothena shares were up 9% to $52.50 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

June 24, 2021 09:36 ET (13:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Bristol Myers Squibb Charts.